Clinical Trial Search

Primary: Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF) — 6.4 months

Primary: Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF) — -0.74; -0.08 percent — p=<0.0001

Primary: Percentage Change in Brachial Artery Flow Mediated (FMD) Vasodilation Between Arms From Baseline to Week 24 — -1.14; 0.25 percentage change — p=0.601

Primary: Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set) — 23.0; 12.4 percent change

Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score — -26.7; -28.6; -21.2 points — p=0.05

Primary: Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and…

Primary: Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set) — -32.8; -47.2 percent change

Primary: Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520 — 187 participants

Primary: The Change From Baseline in Mean Diabetic Neuropathy Pain 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment) — -1.67; -1.55…

Primary: Maternal Confidence Scale — 38; 37 units on a scale — p=0.468

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.20; 11.21; 11.13; 11.05 g/dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.30; 11.32; 11.06; 11.25 g/dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.05; 9.95; 10.05; 11.47 g/dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.02; 10.03; 10.03; 11.55 g/dL

Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 33; 104 participants — p=0.0064